In lung adenocarcinoma, high levels of YTHDF2 and SUMO1 correlate with poor patient prognosis, underscoring the significance of YTHDF2 SUMOylation in cancer regulation and potential therapeutic targeting.[127] Interestingly, PIAS1 enhances the antiviral function of YTHDF2 by promoting its SUMOylation at specific lysine residues, which is crucial for limiting Epstein‐Barr virus (EBV) replication by reducing YTHDF2's binding to EBV transcripts, thus increasing their stability. The gene discussed is YTHDF2; the disease is cancer.